Early
Days 1-7: Reduced inflammation and pain at injury site. Some users report noticeable improvement within 48 hours for acute injuries. Gut issues may show early relief. Injection site may have brief warmth or redness.
Repair & Recovery Gastric PentadecapeptideNot FDA-approved · investigational
BPC-157
Body Protection Compound · Pentadecapeptide BPC
Understand the molecule, evidence, limits, safety, and regulatory context. The calculator and practical protocol now have their own focused page.
Identity
- Name
- BPC-157
- Aliases
- Body Protection Compound · Pentadecapeptide BPC
- Classification
- Gastric Pentadecapeptide · Tissue Repair · Cytoprotective · Anti-inflammatory
- Category
- Repair & Recovery
- Method
- 250mcg – 250 mcg per dose SubQ
What it is
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. The sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is stable in gastric acid, unlike most peptides.
BPC-157 activates multiple repair pathways simultaneously: upregulates VEGF and eNOS for angiogenesis, modulates the NO system, promotes FAK-paxillin pathway for cell migration, and increases GH receptor expression. It is one of the most studied peptides in the regenerative space, with hundreds of animal studies demonstrating tissue repair across tendons, ligaments, muscle, gut, and nerve.
What it is used for
- Tendon and ligament injury recovery
- Muscle tear and strain repair
- Gut healing (leaky gut, IBS, ulcers)
- Post-surgical tissue recovery
- Joint pain and inflammation
- Neuroprotection and nerve repair
How it works
BPC-157 works through multiple complementary mechanisms:
1. Angiogenesis: Upregulates VEGF (vascular endothelial growth factor) and eNOS, promoting new blood vessel formation at injury sites. This increases nutrient and oxygen delivery to damaged tissue.
2. NO System Modulation: Acts as a stabilizer of the nitric oxide system, which regulates blood flow, inflammation, and cellular signaling. Unlike simple NO boosters, BPC-157 appears to normalize the system in both directions.
3. GH Receptor Upregulation: Increases growth hormone receptor expression in target tissues, amplifying the repair effects of both endogenous and exogenous growth hormone.
4. FAK-Paxillin Pathway: Activates focal adhesion kinase signaling, which drives cell migration to injury sites - a critical early step in tissue repair.
5. Collagen Synthesis: Promotes fibroblast activity and organized collagen deposition, supporting structural repair rather than scar formation.
6. Gut-Brain Axis: Interacts with the dopaminergic and serotonergic systems, which may explain its protective effects on both the GI tract and central nervous system.
What to expect
- Reduced pain and inflammation at injury site within first few days
- Improved gut comfort within 1-2 weeks if targeting GI issues
- Accelerated healing of acute injuries (sprains, strains, tears)
- Better sleep quality reported by many users (possibly via gut-brain axis)
- Mild warmth or tingling at injection site (normal, brief)
- Gradual improvement in chronic tendon/joint issues over 4-8 weeks
Response timeline
Mid
Weeks 2-4: Significant healing progress. Chronic injuries begin responding. Tendon and ligament pain markedly reduced. Gut permeability improving. Range of motion and function returning. This is where most users report the most dramatic changes.
Later
Weeks 4-12: Structural repair consolidating. Chronic issues that took months to develop may need this longer timeframe. Collagen remodeling continuing. Some users continue at maintenance dose. Consider cycling off after 8-12 weeks.
Evidence
No published human clinical trials to date. However, BPC-157 has been granted Orphan Drug Designation by the FDA for short bowel syndrome, indicating regulatory recognition of its therapeutic potential. Trials Pharma has initiated clinical trials, but results have not yet been published in peer-reviewed journals.
Extensive animal research spanning 20+ years demonstrates efficacy across multiple tissue types. Studies show accelerated healing of tendons (Achilles, rotator cuff), ligaments (MCL), muscle (crush injury, transection), bone (fractures, segmental defects), gut (ulcers, fistulas, anastomosis leaks, IBD models), nerve (sciatic crush, transection), skin (burns, wounds), and cornea. Notably effective in rat models of NSAID-induced gut damage, alcohol-induced lesions, and surgically-created defects.
Cell culture studies confirm BPC-157 promotes fibroblast migration, endothelial cell tube formation (angiogenesis), and tendon fibroblast outgrowth. Demonstrates direct effects on VEGF, eNOS, and NO pathways at the cellular level.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing ↗
Sikiric P et al · Frontiers in Pharmacology
What the study found. Comprehensive review of BPC 157's pleiotropic wound-healing effects across multiple animal tissue models including muscle, tendon, ligament, bone, gut, brain, and skin.
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro ↗
Huang T et al · Drug Design, Development and Therapy
What the study found. Topical BPC-157 accelerated alkali-burn skin wound closure in rats and promoted endothelial cell proliferation, migration, and VEGF-mediated angiogenesis in vitro.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration ↗
Chang CH et al · Journal of Applied Physiology
What the study found. BPC 157 promoted tendon fibroblast outgrowth, cell survival, and migration in vitro and accelerated Achilles tendon healing in rats.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing ↗
Park CH et al · HSS Journal
What the study found. Narrative review concluded BPC-157 has extensive preclinical support for musculoskeletal healing but minimal human clinical data; should be considered investigational.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review ↗
Vasireddi N et al · HSS Journal
What the study found. Systematic review of BPC-157 in sports medicine found consistent preclinical evidence for tendon, muscle, and ligament repair but no completed randomized human trials at time of review.
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing ↗
Gwyer D et al · Cell and Tissue Research
What the study found. Review of BPC 157 mechanism in soft tissue healing supporting acceleration of repair in tendons, ligaments, and muscles via VEGF, FAK-paxillin, and growth hormone receptor pathways.
Where the evidence runs out
While the animal evidence is extensive and consistent across dozens of independent studies, the lack of published human clinical trial data means all human use is currently off-label/experimental. Anecdotal reports from the peptide community are overwhelmingly positive for injury recovery, but anecdotal evidence has known limitations.
The honest take
“BPC-157 can heal any injury”
Overstated. Animal studies show broad tissue repair capability, but 'any injury' is too absolute. It accelerates natural healing processes - it doesn't regenerate completely destroyed tissue. Structural tears may still need surgical intervention.
“Works in 24-48 hours”
Partially true for acute injuries and pain reduction. Some users report rapid anti-inflammatory effects. However, structural healing (tendon, ligament, collagen) takes weeks regardless of BPC-157 use. It accelerates the timeline, not eliminates it.
“No side effects”
Mostly accurate based on available evidence. Animal studies show remarkably clean safety profile with no established LD50. However, absence of evidence is not evidence of absence - long-term human safety data simply doesn't exist yet.
“Oral BPC-157 works as well as injection”
For gut-specific issues, oral delivery may be effective due to BPC-157's gastric acid stability. For systemic or localized injury repair, SubQ injection near the injury site provides more targeted delivery. Both routes have supporting evidence in animal models.
Side effects and safety
Commonly reported
- Mild injection site redness or warmth (resolves in minutes)
- Occasional lightheadedness immediately post-injection
- Mild GI changes during gut healing (temporary)
Less common and limits
- Rarely reported: mild headache, fatigue in first few days, temporary nausea. BPC-157 has an exceptionally favorable safety profile in animal studies - no LD50 has been established because researchers could not find a lethal dose. However, long-term human safety data does not exist.
Interactions and stacking
Documented together
Wolverine Stack: BPC drives angiogenesis/NO, TB drives actin/cell migration. Most popular repair combination.
SAFE TO MIX. BPC-157 (GEPPPGKPADDAGLV) has no Met/Trp/Cys - no copper oxidation risk. BPC tissue repair + GHK-Cu collagen remodeling. GLOW blend foundation. Draw GHK-Cu last.
BPC targets tissue repair via NO/VEGF, KPV targets inflammation via NF-kB. Gut healing combo.
BPC upregulates GH receptor expression, amplifying Ipamorelin's GH release for enhanced repair.
Keep separate
DAC maleimide group may react with BPC in syringe. Pin CJC-DAC separately.
Acidic pH of NAD+ can denature BPC-157. Different routes anyway (NAD+ is IM).
Thiol chemistry may interfere. Pin separately (Glutathione is IM).
Pharmacokinetics
- Half-life
- 4h
- Peak · Tmax
- 1h
- Elimination
- 20h
- Clearance
- Enzymatic degradation (peptidases); acid-stable in GI tract
- Bioavailability
- ~100% SubQ, ~50% Oral
- Activity duration
- 12-24 hours (VEGF/eNOS and NO system modulation persist beyond plasma clearance)
Regulatory status
Not FDA-approved for any indication. Granted FDA Orphan Drug Designation for short bowel syndrome (Trials Pharma). Available through compounding pharmacies with prescription in some jurisdictions and through research chemical suppliers. Clinical trials initiated but not yet published. All current human use is experimental/off-label. Classified as a research peptide in most countries.
Protocol and calculator
Matching protocol
Open → BPC-157 protocol & calculator
Vial options, sourced dose tiers, reconstitution calculator, numbered preparation sequence, named U-100 syringe visual, storage, and supplies.
References
- Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 2021. Source ↗
- Huang T et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy, 2015. Source ↗
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. Source ↗
- Park CH et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. HSS Journal, 2025. Source ↗
- Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. Source ↗
- Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. Source ↗